Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fabbri, A
Right arrow Articles by Isidori, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fabbri, A
Right arrow Articles by Isidori, A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction Update, Vol.3, No.5 pp.455-466, 1997
© European Society of Human Reproduction and Embryology 1997; all rights reserved

Erectile dysfunction: an overview

A Fabbriz, A Aversa and A Isidori

Cattedra di Andrologia, Dipartimento di Fisiopatologia Medica, Universita di Roma 'La Sapienza', Viale del Policlinico, 155, 00161 Rome, Italy z Corresponding author e-mail: a.fabbri@caspur.it

Abstract

Erectile dysfunction is a common (affecting 10-20 million men in the USA) and multifactorial disease due to organic and/or psychological factors that strongly impairs the quality of life in man. During the past decade many advances in the understanding of pathophysiology of erectile dysfunction have been made and new therapeutic strategies have become available. It has been established that an insufficient production of nitric oxide by penile nerve terminals and/or vascular endothelium may result in an impaired erection or complete impotence. Nowadays, intracavernous injection of vasoactive drugs represents a standardized approach for the diagnosis, and the treatment of choice, for erectile dysfunction, but is not widely accepted by the patients. The possibility of treating erectile dysfunction with intraurethral administration of prostaglandin-E1 has recently become available in the USA, and is a therapy more acceptable to the patients. Other non-invasive medical therapies are undergoing evaluation.

Key words: diagnosis/erection/nitric oxide/therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
N. Toda and T. Okamura
The Pharmacology of Nitric Oxide in the Peripheral Nervous System of Blood Vessels
Pharmacol. Rev., June 1, 2003; 55(2): 271 - 324.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. Aversa, F. Mazzilli, T. Rossi, M. Delfino, A. M. Isidori, and A. Fabbri
Effects of sildenafil (ViagraTM) administration on seminal parameters and post-ejaculatory refractory time in normal males
Hum. Reprod., January 1, 2000; 15(1): 131 - 134.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.